JP2024518426A5 - - Google Patents

Info

Publication number
JP2024518426A5
JP2024518426A5 JP2023568475A JP2023568475A JP2024518426A5 JP 2024518426 A5 JP2024518426 A5 JP 2024518426A5 JP 2023568475 A JP2023568475 A JP 2023568475A JP 2023568475 A JP2023568475 A JP 2023568475A JP 2024518426 A5 JP2024518426 A5 JP 2024518426A5
Authority
JP
Japan
Prior art keywords
aciminib
pharmaceutically acceptable
acceptable salt
combination
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568475A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518426A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/054321 external-priority patent/WO2022238884A1/en
Publication of JP2024518426A publication Critical patent/JP2024518426A/ja
Publication of JP2024518426A5 publication Critical patent/JP2024518426A5/ja
Pending legal-status Critical Current

Links

JP2023568475A 2021-05-11 2022-05-10 投与レジメン Pending JP2024518426A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187023P 2021-05-11 2021-05-11
US63/187,023 2021-05-11
PCT/IB2022/054321 WO2022238884A1 (en) 2021-05-11 2022-05-10 Dosing regimens

Publications (2)

Publication Number Publication Date
JP2024518426A JP2024518426A (ja) 2024-05-01
JP2024518426A5 true JP2024518426A5 (cg-RX-API-DMAC7.html) 2025-05-01

Family

ID=81846537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568475A Pending JP2024518426A (ja) 2021-05-11 2022-05-10 投与レジメン

Country Status (8)

Country Link
US (1) US20240245666A1 (cg-RX-API-DMAC7.html)
EP (1) EP4337205A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024518426A (cg-RX-API-DMAC7.html)
KR (1) KR20240006600A (cg-RX-API-DMAC7.html)
CN (1) CN117396202A (cg-RX-API-DMAC7.html)
CA (1) CA3218550A1 (cg-RX-API-DMAC7.html)
IL (1) IL308095A (cg-RX-API-DMAC7.html)
WO (1) WO2022238884A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120239604A (zh) * 2023-11-01 2025-07-01 深圳市塔吉瑞生物医药有限公司 治疗白血病的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20161416A1 (es) * 2012-05-15 2017-01-08 Novartis Ag Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1

Similar Documents

Publication Publication Date Title
JP2024133475A5 (cg-RX-API-DMAC7.html)
JP2022545835A5 (cg-RX-API-DMAC7.html)
JP2024516363A5 (cg-RX-API-DMAC7.html)
JP2024516795A5 (cg-RX-API-DMAC7.html)
CN106535895A (zh) 丁型肝炎病毒感染的治疗
JP2022116304A (ja) 血液がんの治療のためのＰＰＡＲγアゴニスト
JP2021509395A5 (cg-RX-API-DMAC7.html)
KR20240032789A (ko) 시클로-히스프로를 유효성분으로 포함하는 비만 예방 또는 치료용 약제학적 조성물
JP2025013684A (ja) 重度腎機能障害を有する癌患者に対する治療方法
JP2024517085A5 (cg-RX-API-DMAC7.html)
JP2024518426A5 (cg-RX-API-DMAC7.html)
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP2021522246A5 (cg-RX-API-DMAC7.html)
JP2004525143A5 (cg-RX-API-DMAC7.html)
JP2025517509A5 (cg-RX-API-DMAC7.html)
TW202110448A (zh) Ｐａｒｐ抑制劑聯合ｖｅｇｆｒ抑制劑用於治療卵巢癌或乳腺癌的用途
JP2022177119A5 (cg-RX-API-DMAC7.html)
JP2022502450A5 (cg-RX-API-DMAC7.html)
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤
JP2022504435A5 (cg-RX-API-DMAC7.html)
JP2022524819A (ja) カプシド集合調節剤固体製剤
JP2008501023A (ja) 小児患者での癌の治療
JP2025511402A5 (cg-RX-API-DMAC7.html)
JP2025511401A5 (cg-RX-API-DMAC7.html)
CA2480275A1 (en) Statin therapy for enhancing cognitive maintenance